Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192


Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.

Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM.

Sci Transl Med. 2012 Sep 19;4(152):152ra128.


R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.

Qin M, Huang T, Kader M, Krych L, Xia Z, Burlin T, Zeidler Z, Zhao T, Smith CB.

Int J Neuropsychopharmacol. 2015 Mar 28;18(9). pii: pyv034. doi: 10.1093/ijnp/pyv034.


Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.

Han K, Chen H, Gennarino VA, Richman R, Lu HC, Zoghbi HY.

Hum Mol Genet. 2015 Apr 1;24(7):1813-23. doi: 10.1093/hmg/ddu595. Epub 2014 Nov 28.


Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.

Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ.

J Neurosci. 2010 Aug 11;30(32):10624-38. doi: 10.1523/JNEUROSCI.0402-10.2010.


Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.

Higashimori H, Schin CS, Chiang MS, Morel L, Shoneye TA, Nelson DL, Yang Y.

J Neurosci. 2016 Jul 6;36(27):7079-94. doi: 10.1523/JNEUROSCI.1069-16.2016.


7, 8-Dihydroxyflavone induces synapse expression of AMPA GluA1 and ameliorates cognitive and spine abnormalities in a mouse model of fragile X syndrome.

Tian M, Zeng Y, Hu Y, Yuan X, Liu S, Li J, Lu P, Sun Y, Gao L, Fu D, Li Y, Wang S, McClintock SM.

Neuropharmacology. 2015 Feb;89:43-53. doi: 10.1016/j.neuropharm.2014.09.006. Epub 2014 Sep 16.


Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.

Kang JY, Chadchankar J, Vien TN, Mighdoll MI, Hyde TM, Mather RJ, Deeb TZ, Pangalos MN, Brandon NJ, Dunlop J, Moss SJ.

J Biol Chem. 2017 Apr 21;292(16):6621-6632. doi: 10.1074/jbc.M116.772541. Epub 2017 Feb 17.


Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile x mice.

Sun MK, Hongpaisan J, Lim CS, Alkon DL.

J Pharmacol Exp Ther. 2014 Jun;349(3):393-401. doi: 10.1124/jpet.114.214098. Epub 2014 Mar 21.


Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.

Su T, Fan HX, Jiang T, Sun WW, Den WY, Gao MM, Chen SQ, Zhao QH, Yi YH.

Psychopharmacology (Berl). 2011 May;215(2):291-300. doi: 10.1007/s00213-010-2130-2. Epub 2010 Dec 23.


Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.

Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM.

J Med Genet. 2009 Feb;46(2):94-102. doi: 10.1136/jmg.2008.061796. Epub 2008 Oct 3.


Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.

Pop AS, Levenga J, de Esch CE, Buijsen RA, Nieuwenhuizen IM, Li T, Isaacs A, Gasparini F, Oostra BA, Willemsen R.

Psychopharmacology (Berl). 2014 Mar;231(6):1227-35. doi: 10.1007/s00213-012-2947-y. Epub 2012 Dec 21.


Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome.

Costa L, Spatuzza M, D'Antoni S, Bonaccorso CM, Trovato C, Musumeci SA, Leopoldo M, Lacivita E, Catania MV, Ciranna L.

Biol Psychiatry. 2012 Dec 1;72(11):924-33. doi: 10.1016/j.biopsych.2012.06.008. Epub 2012 Jul 18.


Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of fragile X syndrome.

Padmashri R, Reiner BC, Suresh A, Spartz E, Dunaevsky A.

J Neurosci. 2013 Dec 11;33(50):19715-23. doi: 10.1523/JNEUROSCI.2514-13.2013.


Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Pacey LK, Tharmalingam S, Hampson DR.

J Pharmacol Exp Ther. 2011 Sep;338(3):897-905. doi: 10.1124/jpet.111.183327. Epub 2011 Jun 2.


GABAB receptor-mediated feed-forward circuit dysfunction in the mouse model of fragile X syndrome.

Wahlstrom-Helgren S, Klyachko VA.

J Physiol. 2015 Nov 15;593(22):5009-24. doi: 10.1113/JP271190. Epub 2015 Oct 2.


Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Iliff AJ, Renoux AJ, Krans A, Usdin K, Sutton MA, Todd PK.

Hum Mol Genet. 2013 Mar 15;22(6):1180-92. doi: 10.1093/hmg/dds525. Epub 2012 Dec 18.


Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome.

Liu ZH, Huang T, Smith CB.

Neurobiol Dis. 2012 Mar;45(3):1145-52. doi: 10.1016/j.nbd.2011.12.037. Epub 2011 Dec 29.


Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses.

Antar LN, Li C, Zhang H, Carroll RC, Bassell GJ.

Mol Cell Neurosci. 2006 May-Jun;32(1-2):37-48. Epub 2006 May 2.


Supplemental Content

Support Center